Market Size of Trachoma Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | Middle East and Africa |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Trachoma Treatment Market Analysis
During the time frame of the forecast, the trachoma treatment market is expected to grow at a CAGR of 5.5%.
The COVID-19 pandemic messed up not only the research and development of treatments and medicines for diseases other than COVID-19, but also the global supply chain for pharmaceuticals, which in turn affected the market for trachoma.For example, an article published in January 2021 by Tropical Medicine & Hygiene said that the coronavirus disease (COVID-19) pandemic messed up community-based efforts to control trachoma.Thus, the pandemic had a significant impact on the market initially. Currently, as the COVID-19 pandemic has subsided, the studied market is expected to have stagnant growth during the forecast period of the study.
The major factors driving the growth of the market include the increasing incidence and prevalence of trachoma and favorable government initiatives.
The rising prevalence of trachoma is a major factor driving the market's growth. For instance, according to the data updated by the CDC in June 2022, it is estimated that globally, almost 1.9 million people have vision loss because of trachoma every year, and it causes 1.4% of all blindness worldwide every year. The source also stated that an estimated 136 million people lived in trachoma-endemic areas around the world in 2021 and were at risk of trachoma blindness. Thus, the high prevalence of trachoma around the world is the major factor driving the market's growth.
Also, more efforts by governments around the world are likely to make people more likely to use trachoma drugs.For instance, according to the data updated by the Commonwealth of Australia in June 2021, trachoma is said to be still occurring in some aboriginal and Torres Strait Islander communities in Australia. The Australian government works with the affected states and territories to identify, treat, and prevent this condition, and they also report to the WHO's program to eradicate trachoma across the world.
Also, the Ministry of Health of the Republic of Kenya said in October 2021 that the fight against trachoma, a disease that can cause blindness, got a boost when Kenya and Uganda started a cross-border mass drug administration exercise.The exercise was launched at Alaka's primary school in the Amudat district of Uganda and sought to synchronize drug administration among the residents of west Pokot and Turkana counties with those of neighboring Uganda in an effort to fully eradicate the disease, which is caused by bacteria that attack the inner surfaces of the eyelids.
Thus, the aforementioned factors, such as the rising prevalence of trachoma and the increasing initiatives by the government, are expected to boost market growth. However, the lack of awareness about trachoma and the side effects associated with the drugs is expected to hinder market growth.
